Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 9/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 7/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 6/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 6/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 5/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 2/20 | 0.33 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.33 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13774729 | 1.00 | CHRM2 (0.41) | CHRM2CHRM1CHRM4CHRM3CHRM5 | |
| SCHEMBL14127634 | 1.00 | CHRM2 (0.41) | CHRM2CHRM1CHRM4CHRM3CHRM5 | |
| SCHEMBL18300021 | 0.83 | CHRM2 (0.39) | CHRM2CHRM1CHRM4CHRM3CHRM5 | |
| SCHEMBL18300022 | 0.83 | CHRM2 (0.39) | CHRM2CHRM1CHRM4CHRM3CHRM5 | |
| SCHEMBL1795613 | 0.82 | — | — | |
| SCHEMBL12990820 | 0.82 | CHRM2 (0.48) | CHRM2CHRM1CHRM4CHRM3CHRM5 | |
| SCHEMBL18250835 | 0.82 | CHRM2 (0.48) | CHRM2CHRM1CHRM4CHRM3CHRM5 | |
| SCHEMBL11316954 | 0.80 | CHRM2 (0.39) | CHRM2CHRM1CHRM4CHRM3CHRM5 | |
| SCHEMBL20916933 | 0.79 | ATM (0.37) | — | |
| SCHEMBL13774724 | 0.79 | DPP4 (0.36) | CHRM2CHRM1CHRM4CHRM3CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090176847-A1 | Dicyclooctane Derivatives, Preparation Processes and Medical Uses Thereof | SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) | 2009-07-09 | — | — | US | disclosed |
| EP-2006284-A1 | DICYCLOOCTANE DERIVATES, PREPARATION PROCESSES AND MEDICAL USES THEREOF | Shanghai Hengrui Pharmaceutical Co. Ltd. (CN) | 2008-12-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176847-A1 | Dicyclooctane Derivatives, Preparation Processes and Medical Uses Thereof | DPP4, DPP7, DPP8 | CHRM2 2577/4885CHRM1 3531/4885CHRM4 2801/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.